Johan Widmark | 2024-02-05 08:00
A game changer in the immune analysis field
After acquiring Psyros Diagnostics in 2022, Prolight is advancing the development of a single molecule counting (digital) immuno analysis device that enables detection of biomarkers at extremely low concentrations, using a single drop of blood. In Sweden, 250,000 patients seek medical attention for chest pains annually, of which less than 10% are ultimately diagnosed with heart attacks. Current diagnostic methods result in long waiting times, but Prolight’s device provides results in 10 minutes, reducing financial burden and patient suffering. While this technique integrates the possibility of simultaneous testing of multiple biomarkers (multiplexing), Prolight is initially focusing on tests for the cardiac biomarker, troponin.
Significant market potential for POCT
Prolight has significant growth potential not only in the USD 1.5 billion troponin testing market but also in other valuable biomarkers such as B-type natriuretic peptide (BNP) for suspected heart failure and D-Dimer for suspected blood clot formation, a market valued at USD 1.2 billion. Additionally, there are opportunities to expand their point-of-care technology into other areas like Neuropathology, Immune System Dysfunction such as sepsis, and Virus Detection, representing multi-billion-dollar markets. Considering the immense long-term potential of Prolight’s technology, we have focused our valuation approach primarily on the troponin biomarker while also considering BNP and D-Dimer as potential additional verticals.
Expect commercial launch in partner setup by 2026
Following the proof-of-performance announced in mid-June, followed by whole blood in November 2023, Prolight now focuses on the development of the commercial instrument prototype for digital immune analysis, in partnership with Integrated Technologies Limited (ITL) and the preparations for the IVDR certification. This is expected to take 24 months, due to the shortage of Notified Bodies, which is why the Company predicts commercialization of the troponin test by early 2026, followed by BNP in 2028 and D-Dimer in 2030. This roadmap is however highly uncertain.
Using an estimated price of USD 20 per troponin POC-test, an annual suspected heart attack incidence rate of 2.5%, peak market penetration of 30% by 2034 (10m tests) would translate to sales of SEK 2.4bn. Through many possible rollout scenarios, we expect Prolight to rollout together with a commercial partner and receive a total of USD 20m of upfront payments, and a 15% royalty on future sales, at an estimated 75% cumulative probability to reach commercialization. Adding the potential for BNP and D-Dimer POC-tests at 12.5% royalty, this translates to a NPV of SEK 680m. Following the rights issue in December 2023 (76% subscription) this motivates a fair value of SEK 1.1-1.2 per share, factoring in additional new equity of a total of around SEK 100m. Should Prolight manage to raise the max amount in TO6 + TO7 at SEK 169m the surplus could be used to expand the scope and accelerate timeline.
DISCLAIMER
This commissioned research report is for informational purposes only and is to be considered marketing communication. This research does not constitute investment advice and is not a solicitation to buy shares. Information provided here or on Emergers’ website emergers.se is not intended to be financial advice. This research shall not be construed as a recommendation or solicitation to invest in the companies described. Emergers cannot be held liable for either direct or indirect damages caused by decisions made on the basis of information in this analysis. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.
This material is not intended to be financial advice. This material has been commissioned by the Company in question and prepared and issued by Emergers, in consideration of a fee payable by the Company. Emergers charges a standard fee for the production and broad dissemination of a detailed note following by regular update notes. Fees are paid upfront in cash without recourse. Emergers may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.
Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained herein represent those of the research analyst at Emergers at the time of publication. The company has been given the opportunity to influence factual statements before publication, but forecasts, conclusions and valuation reasoning are Emergers’ own. Forward-looking information or statements contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.
Exclusion of Liability: To the fullest extent allowed by law, Emergers shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained in this material.
No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Emergers’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in this material may not be eligible for sale in all jurisdictions or to certain categories of investors. Investors are encouraged to seek additional information as well as consult a financial advisor prior to any investment decision.
Investment in securities mentioned: Emergers has a restrictive policy relating to personal dealing and conflicts of interest. Emergers does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Emergers may have a position in any or related securities mentioned in this report, subject to Emergers’ policies on personal dealing and conflicts of interest.
Copyright: Copyright 2023 Incirrata AB (Emergers)
United Kingdom
This document is prepared and provided by Emergers for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the ”FPO”) (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.
This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.
United States
Emergers relies upon the ”publishers’ exclusion” from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Emergers does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
